The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions

Name: Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions
Uploaded: 2020-07-01T13:35:39Z
Duration: 2 min 31 s
Description: Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, describes a retrospective analysis on the efficacy of second-line chemotherapy in patients enrolled in the PROOF study (NCT03773302) with advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Milind Javle • 1 Jul 2020

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer FOLFOX Gemcitabine Infigratinib

ABC-06 PROOF

Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, describes a retrospective analysis on the efficacy of second-line chemotherapy in patients enrolled in the PROOF study (NCT03773302) with advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).